Boc-Gly-Gly-Phe-Gly-OH TFA

Boc-Gly-Gly-Phe-Gly-OH TFA Catalog number: BADC-01238

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

Category
ADCs Linker
Product Name
Boc-Gly-Gly-Phe-Gly-OH TFA
Catalog Number
BADC-01238
Molecular Formula
C22H29F3N4O9
Molecular Weight
550.48

Ordering Information

Catalog Number Size Price Quantity
BADC-01238 -- $--
Inquiry
Description
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).
Synonyms
Boc-Gly-Gly-Phe-Gly-OH trifluoroacetic acid; N-tert-butoxycarbonyl-glycyl-glycyl-L-phenylalanyl-glycine trifluoroacetic acid
IUPAC Name
2-[[(2S)-2-[[2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid;2,2,2-trifluoroacetic acid
Canonical SMILES
CC(C)(C)OC(=O)NCC(=O)NCC(=O)NC(CC1=CC=CC=C1)C(=O)NCC(=O)O.C(=O)(C(F)(F)F)O
InChI
InChI=1S/C20H28N4O7.C2HF3O2/c1-20(2,3)31-19(30)23-10-15(25)21-11-16(26)24-14(18(29)22-12-17(27)28)9-13-7-5-4-6-8-13;3-2(4,5)1(6)7/h4-8,14H,9-12H2,1-3H3,(H,21,25)(H,22,29)(H,23,30)(H,24,26)(H,27,28);(H,6,7)/t14-;/m0./s1
InChIKey
RXCXUMYQOKOAGZ-UQKRIMTDSA-N
Sequence
Boc-GGFG-OH.TFA
Solubility
H2O: 125 mg/ml (22707 mm, need ultrasonic)
Appearance
Powder
Purity
>98%
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature
Storage
Store at -20 °C, keep in dry and avoid sunlight.

Boc-Gly-Gly-Phe-Gly-OH TFA, a peptide with diverse applications in biochemical and pharmaceutical research, serves as a versatile tool in various domains. Here are four key applications presented with high perplexity and burstiness:

Peptide Synthesis: Functioning as an intermediary in the synthesis of peptides, Boc-Gly-Gly-Phe-Gly-OH TFA plays a pivotal role in peptide assembly, acting as a foundational unit for constructing larger, more intricate peptides. This function is indispensable for crafting tailored peptides for both research endeavors and therapeutic applications, showcasing the peptide’s versatility in the realm of peptide synthesis.

Protein-Protein Interaction Studies: Delving into the intricacies of protein-protein interactions, researchers harness the power of Boc-Gly-Gly-Phe-Gly-OH TFA to explore how specific peptide sequences influence the binding affinity and specificity of proteins. These studies are paramount in the realm of drug discovery and molecular mechanism comprehension, shedding light on the nuanced interactions that drive biological processes.

Drug Delivery Systems: Introducing Boc-Gly-Gly-Phe-Gly-OH TFA into drug delivery systems enhances the stability and bioavailability of therapeutic peptides, revolutionizing the realm of drug administration. By modifying peptide structures, this peptide assists in formulating more potent and targeted treatments, thus propelling advancements in the field of precision medicine and improving patient outcomes.

Bioconjugation: In the realm of bioconjugation techniques, Boc-Gly-Gly-Phe-Gly-OH TFA emerges as a valuable asset, facilitating the linking of peptides to various molecules such as drugs or imaging agents. This process enables the targeted delivery of therapeutic compounds and the visualization of biological processes, underscoring the peptide’s pivotal role in diagnostics and therapeutics, demonstrating its versatility and adaptability in diverse applications.

1. Radioiodine therapy of thyroid autonomy
Jérôme Clerc Q J Nucl Med Mol Imaging. 2021 Jun;65(2):138-156. doi: 10.23736/S1824-4785.21.03340-9. Epub 2021 Feb 10.
Radioiodine therapy (RIT) of thyroid functional autonomy (TFA) is rapidly evolving, though it has been recognized for decades as a very effective treatment of toxic nodular varieties. Indeed, TFA is a frequent cause of persistent subclinical hyperthyroidism, which should be regarded as a new metabolic syndrome, with well-established adverse cardio-vascular consequences. Sensitive TSH assays and multiparametric ultrasounds are not accurate enough to reliably diagnose TFA and identify its main variants, unifocal, multifocal (UFA/MFA) and disseminated autonomy (DISA). Modern diagnostic tools are extensively presented and rely upon Thyroid Scan imaging and quantification. A new relationship allows predicting at baseline, an excess of 123I uptake as compared to the TSH stimulation in compensated TFA. Suppressed TS are useful with either isotope, otherwise. Diagnosis of the DISA variant is presented as compared to Graves' disease. Dosimetry has some specificity in TFA work-up. Indeed, the spatial distribution of the dose is as important as the mean value itself and can be eventually controlled by adjusting the TSH level with the smart use of LT3 or antithyroid drug therapy (ATD). A review of the different ways to determine the target mass from anatomical to functional approaches is presented. Main clinical and dosimetric published results of RIT are summarized according to clinical goals. Endogenous TSH stimulation using an ATD preparation has promising results in reducing big autonomously functioning goiters. Finally, we report preliminary successful results of preventive RIT using short term LT3 suppression in compensated TFA, with low administered activities and low rate of hypothyroidism.
2. Development of a theory-informed questionnaire to assess the acceptability of healthcare interventions
Mandeep Sekhon, Martin Cartwright, Jill J Francis BMC Health Serv Res. 2022 Mar 1;22(1):279. doi: 10.1186/s12913-022-07577-3.
Background: The theoretical framework of acceptability (TFA) was developed in response to recommendations that acceptability should be assessed in the design, evaluation and implementation phases of healthcare interventions. The TFA consists of seven component constructs (affective attitude, burden, ethicality, intervention coherence, opportunity costs, perceived effectiveness, and self-efficacy) that can help to identify characteristics of interventions that may be improved. The aim of this study was to develop a generic TFA questionnaire that can be adapted to assess acceptability of any healthcare intervention. Methods: Two intervention-specific acceptability questionnaires based on the TFA were developed using a 5-step pre-validation method for developing patient-reported outcome instruments: 1) item generation; 2) item de-duplication; 3) item reduction and creation; 4) assessment of discriminant content validity against a pre-specified framework (TFA); 5) feedback from key stakeholders. Next, a generic TFA-based questionnaire was developed and applied to assess prospective and retrospective acceptability of the COVID-19 vaccine. A think-aloud method was employed with two samples: 10 participants who self-reported intention to have the COVID-19 vaccine, and 10 participants who self-reported receiving a first dose of the vaccine. Results: 1) The item pool contained 138 items, identified from primary papers included in an overview of reviews. 2) There were no duplicate items. 3) 107 items were discarded; 35 new items were created to maximise coverage of the seven TFA constructs. 4) 33 items met criteria for discriminant content validity and were reduced to two intervention-specific acceptability questionnaires, each with eight items. 5) Feedback from key stakeholders resulted in refinement of item wording, which was then adapted to develop a generic TFA-based questionnaire. For prospective and retrospective versions of the questionnaire, no participants identified problems with understanding and answering items reflecting four TFA constructs: affective attitude, burden, perceived effectiveness, opportunity costs. Some participants encountered problems with items reflecting three constructs: ethicality, intervention coherence, self-efficacy. Conclusions: A generic questionnaire for assessing intervention acceptability from the perspectives of intervention recipients was developed using methods for creating participant-reported outcome measures, informed by theory, previous research, and stakeholder input. The questionnaire provides researchers with an adaptable tool to measure acceptability across a range of healthcare interventions.
3. Global Surveillance of trans-Fatty Acids
Chaoyang Li, Laura K Cobb, Hubert W Vesper, Samira Asma Prev Chronic Dis. 2019 Oct 31;16:E147. doi: 10.5888/pcd16.190121.
Trans-fatty acid (TFA) intake can increase the risk of coronary heart disease (CHD) morbidity and mortality and all-cause mortality. Industrially produced TFAs and ruminant TFAs are the major sources in foods. TFA intake and TFA-attributed CHD mortality vary widely worldwide. Excessive TFA intake is a health threat in high-income countries; however, it is also a threat in low- and middle-income countries (LMICs). Data on TFA intake are scarce in many LMICs and an urgent need exists to monitor TFAs globally. We reviewed global TFA intake and TFA-attributed CHD mortality and current progress toward policy or regulation on elimination of industrially produced TFAs in foods worldwide. Human biological tissues can be used as biomarkers of TFAs because they reflect actual intake from various foods. Measuring blood TFA levels is a direct and reliable method to quantify TFA intake.
The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Why Choose BOC Sciences?

Customer Support

Providing excellent 24/7 customer service and support

Project Management

Offering 100% high-quality services at all stages

Quality Assurance

Ensuring the quality and reliability of products or services

Global Delivery

Ensuring timely delivery of products worldwide

Questions & Comments
Verification code
Send Inquiry
Verification code
Inquiry Basket